Clinical Trial Update: Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101 [Phase 2, Phase 3]

View source ↗

Summary

A continuation study evaluating recombinant and protein-free Factor VIII (rAHF-PFM) in pediatric Hemophilia A patients conducted in Canada; completed phase 2/3 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• rAHF-PFM (recombinant protein-free manufactured factor VIII)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia A | Phase 2, Phase 3 | Status: COMPLETED